Advertisement

Research Article Free access | 10.1172/JCI114299

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

C Ferrari, A Penna, A Bertoletti, A Cavalli, A Valli, C Schianchi, and F Fiaccadori

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Ferrari, C. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Penna, A. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Bertoletti, A. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Cavalli, A. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Valli, A. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Schianchi, C. in: PubMed | Google Scholar

Cattedra di Malattie Infettive, Università di Parma, Italy.

Find articles by Fiaccadori, F. in: PubMed | Google Scholar

Published October 1, 1989 - More info

Published in Volume 84, Issue 4 on October 1, 1989
J Clin Invest. 1989;84(4):1314–1319. https://doi.org/10.1172/JCI114299.
© 1989 The American Society for Clinical Investigation
Published October 1, 1989 - Version history
View PDF
Abstract

14 hepatitis B vaccine recipients who showed high titers of anti-hepatitis B surface antibodies in serum after booster immunization with a polyvalent hepatitis B surface antigen vaccine that contained trace amounts of hepatitis B virus (HBV) preS1 and preS2 envelope antigens were studied for their in vitro T cell response to these antigens. All 14 subjects displayed a significant proliferative T cell response to the S/p25 envelope region encoded polypeptide; 8 also responded to preS1, while only 1 showed a significant level of T cell proliferation to preS2. Limiting dilution analysis demonstrated that the frequency of preS-specific T cells in two of these vaccine recipients was higher than that of S/p25-specific T cells. T cell cloning was then performed and a total of 29 HBV envelope antigen-reactive CD4+ cloned lines were generated from two preS-responsive vaccines. 21 of these lines were S/p25 specific, 7 preS1 specific, and 1 preS2 specific. Taken together, all these results suggest that the preS1 antigen may function as a strong T cell immunogen in man.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (October 1, 1989): No description
Advertisement
Advertisement